Abvc Biopharma (ABVC) Net Cash Flow (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Net Cash Flow came in at -$1.2 million in Q1 2026, down 970.7% YoY from $136591.4 in Q1 2025, and down 358.08% on a QoQ basis from $460828.0 in Q4 2025.
Abvc Biopharma (ABVC) Net Cash Flow (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 17 years of Net Cash Flow data on file, last reported at -$1.2 million in Q1 2026.
- Quarterly Net Cash Flow fell 970.7% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30461.0 (down 77.77% YoY) and the FY2025 annual result came in at $442906.0, up 158.07% from the prior year.
- Net Cash Flow retreated to -$1.2 million in Q1 2026, from $460828.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $1.0 million in Q2 2025 to a low of -$3.5 million in Q2 2022.
- A 5-year average of -$521808.2 and a median of -$237869.0 in 2023 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 225.8% in 2025, down 1257.09% in 2025.
- Tracing ABVC's Net Cash Flow over 5 years: stood at -$797857.0 in 2022, then surged by 70.19% to -$237869.0 in 2023, then plunged by 54.0% to -$366312.0 in 2024, then soared by 225.8% to $460828.0 in 2025, then tumbled by 358.08% to -$1.2 million in 2026.
- The last three Net Cash Flow figures came in at -$1.2 million (Q1 2026), $460828.0 (Q4 2025), and -$274219.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 225.59 Mn |
| 10 | Abvc Biopharma | 23.97 Mn | 23.97 Mn | - | -119,735.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -119,735.00 |
| Jun 30, 2026 | -119,735.00 |
| Mar 31, 2026 | -1.19 Mn |
| Mar 31, 2026 | -1.19 Mn |
| Dec 31, 2025 | 460,828.00 |
| Dec 31, 2025 | 460,828.00 |
| Sep 30, 2025 | -274,219.00 |
| Sep 30, 2025 | -274,219.00 |
| Jun 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | -111,077.00 |
| Mar 31, 2025 | -111,077.00 |
| Dec 31, 2024 | -366,312.00 |
| Dec 31, 2024 | -366,312.00 |
| Sep 30, 2024 | 23,699.00 |
| Sep 30, 2024 | 23,699.00 |
| Jun 30, 2024 | 590,731.00 |
| Jun 30, 2024 | 590,731.00 |
| Mar 31, 2024 | -31,669.00 |
| Mar 31, 2024 | -31,669.00 |